LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

18.59 -0.64

Buy Sell

Overview

Share price change

24h

Current

Min

18.2

Max

19.3

Key metrics
By Trading Economics
Income	102K -128M
EPS	-0.69
Employees	507
EBITDA	-9.8M -135M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+90.71% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-42M 2.9B
Previous open	19.23
Previous close	18.59

News Sentiment

By Acuity

50%

148 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.355 / 16.44 Support & Resistance

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 May 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 May 2026, 16:49 UTC

Earnings

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 May 2026, 16:26 UTC

Major Market Movers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 May 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 May 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 May 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 May 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 May 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 May 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 May 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 May 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 May 2026, 21:53 UTC

Earnings

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 May 2026, 21:02 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 May 2026, 20:55 UTC

Earnings

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 May 2026, 20:30 UTC

Hot Stocks

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 May 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 May 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 May 2026, 20:20 UTC

Earnings

Webull 1Q Adj EPS 3c >BULL

21 May 2026, 20:20 UTC

Earnings

Webull 1Q Rev $159.9M >BULL

21 May 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 May 2026, 20:18 UTC

Earnings

Webull 1Q Loss/Shr 4c

21 May 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 May 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 May 2026, 18:58 UTC

Earnings

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 May 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 May 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 May 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 May 2026, 17:01 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 May 2026, 16:20 UTC

Market Talk

Earnings

Stellantis Targets Distant but Constructive -- Market Talk

21 May 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

90.71% upside

12 Months Forecast

Average 35.91 USD 90.71%

High 42 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.355 / 16.44Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

148 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.